Ligand Reports First Quarter 2025 Financial Results
Provided By GlobeNewswire
Last update: May 8, 2025
First quarter performance driven by strong portfolio royalty revenue growth of 44%
Strengthened commercial portfolio and pipeline through strategic transactions with Channel Therapeutics and Castle Creek Biosciences
Read more at globenewswire.comNASDAQ:LGND (10/17/2025, 3:02:11 PM)
183.95
+3.18 (+1.76%)
Find more stocks in the Stock Screener
